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In patients with cancer, defects of the immune response against infection arise from several factors acting either concomitantly or sequentially; certainly, major roles are played by the underlying disease and by the medical therapies developed to treat it. Indeed, many of the technologies and pharmacological tools used in modern medicine have the potential to facilitate the onset of infection caused by microorganisms that once were considered to be nonpathogenic or saprophytic. We have learned that the ability of a microorganism to cause disease is a function not only of its intrinsic virulence but also of the immunologic competence of the host and the disruption of the host's defense barriers. As new cancer treatments are introduced, evolution in the epidemiological and microbiological profiles of infections in patients with cancer brings new challenges for infectious diseases specialists.
Neutropenia (defined by an absolute granulocyte count of !500 cells/mm 3 ) is the best characterized form of immunocompromise in patients undergoing treatment for cancer, although the importance of mechanical barriers damaged by mucositis is increasingly appreciated. In addition, the effects of commensal flora and organ function alteration caused by the underlying disease and by medical practices are a subject of recent investigation. Among medications that increase the risk of infection are monoclonal antibodies directed against cell receptors on B and T cell precursors used to treat lymphoma and acute leukemia; these medications have added new problems and have disclosed new aspects of great interest for infectious disease specialists [1] . Interestingly, some genetic factors are being identified that might be able to affect the risk of infection in patients with cancer. A recent study demonstrated that genetically determined serum deficiency of mannosebinding lectin (MBL), an important component of the innate immune system, might have some influence on the duration of fever during neutropenic episodes [2] . In fact, the median duration of fever for patients with MBL deficiency was twice that for patients in the control group (20.5 vs. 10.0 days; ), and patients P p .014 with the lowest serum concentrations of MBL (!1000 mg/L) at the time of diagnosis had febrile neutropenia for a greater median number of days of than did patients with higher serum concentrations of MBL [2] .
Understanding the contribution of all these deficits to the risk of serious infection should allow clinicians to tailor antibiotic therapy to each patient's situation, although it is often very difficult to differentiate simultaneous effects caused by different drugs and interventions in the individual patient. The present article reviews recent research on infections in patients with cancer, with regard to the selection and application of empirical antibiotic therapy. For this review, we relied mainly on data from the many clinical trials of empirical antibiotic therapy performed by the International Antimicrobial Therapy Group (IATG) of the European Organization for Research and Treatment of Cancer (EORTC) during the past 25 years [3] .
MORTALITY DURING EPISODES OF FEBRILE NEUTROPENIA
In recent years, treatment of patients with febrile neutropenia has improved greatly, especially with regard to control of bacterial infections. Especially telling is the fact that, among ∼800 documented cases of bacteremia observed in the 8 EORTC-IATG therapeutic trials performed from 1978 to 1994 (I, II, III, IV, V, VIII, IX, and XI), the overall mortality rate decreased from 21% to 7%. In particular, the 30-day rates of death due to any cause for patients with gram-negative or -positive bacteremia are now as low as 10% and 6%, respectively [4] . These results represent a dramatic improvement, compared with, for example, the findings of a classic study of bacteremia due to gram-negative organisms performed in 1962, in which the mortality rate in patients with severe underlying disease approached 90% [5] and compared with the findings of the first EORTC-IATG study performed in 1978. In the latter study, 120% of patients with gram-negative sepsis and ∼15% of those with gram-positive sepsis died [6] . Although there likely are multiple reasons for these improvements, the strategy that calls for rapid treatment with empirical, broad-spectrum antibacterial therapy using very active antimicrobial compounds after the development of fever has, no doubt, played a pivotal role.
Although similar encouraging trends have been found in many institutions in both Europe and the United States, they were not confirmed in a recent report from the Surveillance and Control of Pathogens of Epidemiologic Importance Project, which involved 2340 patients with underlying malignancies and nosocomial bloodstream infections [7] . In that study, unexpectedly high mortality rates associated with infections caused by coagulase-negative staphylococci (33.4%) and other gram-positive pathogens (e.g., methicillin-susceptible Staphylococcus aureus [22. 8%] and methicillin-resistant S. aureus [17. 7%]) were observed [7] . Although it is agreed that the EORTC data might have the bias of being derived from clinical trials of empirical antibiotic therapy in which patients are selected according to inclusion and exclusion criteria, it is nevertheless very difficult to interpret these discrepancies without highlighting very important differences between study populations and methods of evaluating the time to and cause of death. This issue has also been commented on by investigators from the M. D. Anderson Cancer Center (Houston, TX) [8] .
They underlined the fact that bacteremia accounts for only 35% of infections among patients with hematologic malignancies and 20% of infections among patients with solid tumors. In addition, infections occurring at other sites (e.g., pneumonia) or polymicrobial infections had higher associated mortality rates [8] .
ETIOLOGY OF INFECTION IN FEBRILE NEUTROPENIA
Trends in mortality reflect the successful adaptation of empirical anti-infective therapy to patterns of infective microorganisms. The well-documented shift in the balance of predominant pathogens from gram negative to gram positive occurred internationally during the 1980s, and gram-positive pathogens continue to be the more common infecting organisms in most hospitals [7, 9] (figure 1). The reasons for this modification of the pattern of infecting pathogens are unclear. Treatment for cancer has become more intensive and is associated with more severe oral mucositis and diarrhea, leading to major damage of mucosal barriers and an increased risk of infection due to resident gram-positive oral flora. In addition, patients with cancer are fitted with partially or totally implantable intravenous catheters more often than in the past, a fact that might explain the increasing number of staphylococcal infections [10] .
The selective pressure of antibiotics, such as third-generation cephalosporins and fluoroquinolones that are more active against gram-negative than against gram-positive bacteria, may also have played a relevant role. Elting et al. [11] showed that use of fluoroquinolones was one of the factors significantly associated with development of streptococcal bacteremia, especially when used in combination with H 2 blockers and other antacids. These phenomena were probably due to increased colonization of the gastric and esophageal flora by oral streptococci. Certainly, the widespread use of antibacterial prophylaxis with fluoroquinolones played a role in shifting the etiological pattern of bacteremia and was also associated with a decrease in the rate of bacteremia as the cause of febrile neutropenia [12] .
Very recently, there have been some indications that the etiological pattern of pathogens that cause bacteremia is changing again. For example, Haupt et al. [13] showed an increase of 3.4% per year in the incidence of gram-negative bacteremia among children treated for solid tumors from 1985 to 1996 in a single institution. Similarly, 2 articles showed an increasing rate of gram-negative infections among patients with late-onset bacteremia following bone marrow transplantation [14, 15] . In another study, Gaytán-Martínez et al. [16] found that Escherichia coli was the pathogen isolated most often during episodes of primary bacteremia among patients with cancer and febrile neutropenia. Finally, in the most recent trial of empirical antibiotic therapy performed by the EORTC-IATG, there was both an increase in the rate of bacteremia associated with febrile and neutropenic episodes (from 23% to 28%;
) and an increase in the P p .03 proportion of gram-negative bacteremia (from 6.5% to 12%; ) [17] . It is unclear to what extent the new increase in P ! .001 the proportion of gram-negative bacteremia was associated with either a decrease in the use of quinolone prophylaxis or an increase in resistance to quinolones. Indeed, the increase in gram-negative bacteremia was also observed in health-care centers in which quinolone prophylaxis had never been used [13] , in health-care centers in which quinolone prophylaxis had been recently discontinued [7] , and in centers in which ciprofloxacin was still being used [16] .
It is too soon to know whether these increases will continue and become a trend, but it should be emphasized that infections caused by gram-negative organisms have not disappeared from the scene. The importance of coverage for gram-negative pathogens in empirical therapy remains high, not only because of their virulence [18] , but also because they still cause the majority of infections, if sites of infection other than blood are considered. For example, in the previously mentioned report from the M. D. Anderson Cancer Center [8] , although grampositive organisms were still prevalent as the cause of singleorganism bacteremia, gram-negative organisms were predominant at most other sites of infection. In addition, many gram-negative organisms were isolated from polymicrobial infections, which have more than doubled in frequency since the early 1970s [8] .
The emergence of unusual organisms as pathogens is found in many institutions. In particular, some health-care centers report an increasing incidence of infections due to both vancomycin-sensitive and -resistant enterococci and extendedspectrum b-lactamase-producing, gram-negative organisms [9, [19] [20] [21] in patients with cancer. Increases in nosocomial infections due to Stenotrophomonas maltophilia have been reported among patients who received broad-spectrum antibiotics [22] . In addition, species usually considered to be relatively innocuous, such as Corynebacterium species, have been found to cause serious infections [23] . Vigilant surveillance practices are needed to detect outbreaks of these infections and to devise appropriate responses.
RISK STRATIFICATION
A patient's medical history, underlying illness, and treatment have long been recognized as playing a role in each patient's risk of acquiring serious infection and of dying from infection. The fatal consequences of prolonged, severe granulocytopenia among patients who develop infections were quantified by Bodey et al. [24] . This work lead to the widespread practice of immediate hospitalization and administration of iv broadspectrum antibiotic therapy for all patients with febrile neutropenia. Since publication of the study by Bodey et al. [24] , additional criteria for determining immunocompromised patients' risk of acquiring serious infection have been evaluated by use of a wide variety of approaches. These investigations have the goal of specifying optimum care while avoiding un- necessary hospitalizations and overuse of broad-spectrum antibiotic therapy. In general, researchers seek to identify patients with a low risk of acquiring serious infection who can safely be treated with short periods of hospitalization and early discharge, outpatient therapy, or oral antibiotic therapy. All approaches rely heavily on the clinical impression of the patients' conditions and on practical considerations for outpatient treatment at each institution. Talcott et al. [25] classified patients with febrile neutropenia into 4 groups, according to the status of their underlying disease and comorbidity on the first day of fever. Patients in 3 of the 4 groups were considered to be at high risk for major complications and to require hospitalization and were defined as follows: (1) patients who were already hospitalized for cancer treatments; (2) outpatients who had underlying illness that either was in remission or was not progressing but who had significant comorbid symptoms, such as pain, nausea, and volume depletion; and (3) outpatients whose underlying illness was uncontrolled. The fourth group of patients had uncomplicated fever and neutropenia only and were expected to have few complications. This hypothesis was validated in a study of larger groups of patients [26] . However, in a third study performed by the same group of investigators [27] , the clinical prediction rule seemed not to be able to discriminate satisfactorily between favorable and unfavorable outcomes. In that report, 14 (47%) of 30 patients discharged after 2 days from the time of onset of fever had to change treatment, and 9 (30%) had to be readmitted to the hospital because medical complications developed [27] . As shown in table 1, these and other studies allowed characterization of an "ideal" low-risk patient [28] .
Similar attributes were used to determine eligibility for 2 clinical trials in which low-risk patients were treated with empirical antibiotic therapy at home. This approach was found to be generally feasible in a randomized trial that, for carefully selected patients with febrile neutropenia, compared oral ofloxacin at home or in the hospital [29] . In a second trial, pediatric patients with cancer who were at low risk of developing complications were randomized to receive outpatient therapy with oral ciprofloxacin or iv ceftazidime [30] . Hospitalization was required in 14% of episodes of febrile neutropenia in which the treatment was oral ciprofloxacin and in 21% of episodes of febrile neutropenia in which the treatment was iv ceftazidime, among patients who were originally treated at home. Both reports emphasized the importance of frequent monitoring and strict vigilance during the period of neutropenia, to achieve successful outcomes [29, 30] . Laboratory parameters, including evaluation of serum concentrations of Creactive protein and procalcitonin, were also used to evaluate the risk of serious medical complications and the patient's clinical course. These parameters have been included among those able to predict the occurrence of bacterial infections in patients with neutropenia, although their clinical significance is uncertain [18] .
The Multinational Association for Supportive Care in Cancer developed a scoring system to identify low-risk patients with cancer and febrile neutropenia [31] . Serious medical complications were identified in a derivation set of 756 patients and were prospectively weighted with a numerical score for a validation set of 383 patients (table 2) . A score of !21 was chosen as a threshold because of a low misclassification rate (21%), a large proportion of patients identified as being at low risk (73%), and a high positive predictive value (94%) in the derivation set of patients [31] .
CONCLUSION
Although rates of death due to febrile neutropenia continue to decrease, new epidemiological and microbiological patterns continue to challenge clinicians. In clinical studies that assess the risk of major complications, burden of illness or severity of symptoms carries considerable weight. In daily practice, clinical judgment of similar factors often affects the decision of whether a patient can be sent home. Although the studies are important for identifying parameters and overall characteristics of risk, every patient is different and deserves focused attention to determine the best course of treatment.
